FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties

Trends in Endocrinology and Metabolism

Volumn 26, Issue 11, 2015, Pages 608-617

  Kharitonenkov, Alexei ^a   DiMarchi, Richard ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Drug development; FGF21; FGFR; Hormones; KLB; Metabolic regulation

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR;

HORMONAL REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; REVIEW; ANIMAL; METABOLISM; PHYSIOLOGY;

ANIMALS; FIBROBLAST GROWTH FACTORS; HUMANS;

EID: 84945912355     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2015.09.007     Document Type: Review

References (100)

1. Kharitonenkov A., et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005, 115:1627-1635.
2. Adams A.C., et al. FGF21 requires betaklotho to act in vivo. PLoS ONE 2012, 7:e49977.
3. Ding X., et al. betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012, 16:387-393.
4. Adams A.C., et al. Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS ONE 2012, 7:e38438.
5. Itoh N. FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases. Front. Endocrinol. 2014, 5:107.
6. Kurosu H., et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 2007, 282:26687-26695.
7. Kharitonenkov A., Larsen P. FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol. Metab. 2011, 22:81-86.
8. Adams A.C., et al. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2012, 2:31-37.
9. Foltz I.N., et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci. Transl. Med. 2012, 4:162ra53.
10. Veniant M.M., et al. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS ONE 2012, 7:e40164.
11. Holland W.L., et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013, 17:790-797.
12. Lin Z., et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013, 17:779-789.
13. Fisher F.M., et al. Fibroblast Growth Factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 2014, 147:1073-1083.
14. Fisher F.M., et al. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 2011, 152:2996-3004.
15. Li Y., et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology 2014, 146:539-549.
16. Wu X., et al. Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE mice. Heart Vessels 2014, 30:657-668.
17. Johnson C.L., et al. Silencing of the Fibroblast growth factor 21 gene is an underlying cause of acinar cell injury in mice lacking MIST1. Am. J. Physiol. Endocrinol. Metab. 2014, 306:E916-E928.
18. Feingold K.R., et al. FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology 2012, 153:2689-2700.
19. Izumiya Y., et al. FGF21 is an Akt-regulated myokine. FEBS Lett. 2008, 582:3805-3810.
20. Hojman P., et al. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 2009, 58:2797-2801.
21. Mashili F.L., et al. Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab. Res. Rev. 2011, 27:286-297.
22. Lee M.S., et al. Fibroblast growth factor-21 protects human skeletal muscle myotubes from palmitate-induced insulin resistance by inhibiting stress kinase and NF-kappaB. Metabolism 2012, 61:1142-1151.
23. Suomalainen A., et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol. 2011, 10:806-818.
24. Planavila A., et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat. Commun. 2013, 4:2019.
25. Patel V., et al. Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PLoS ONE 2014, 9:e87102.
26. Liu S.Q., et al. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci. Rep. 2013, 3:2767.
27. Lee P., et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab. 2014, 19:302-309.
28. Fisher F.M., et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012, 26:271-281.
29. Hondares E., et al. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab. 2010, 11:206-212.
30. Emanuelli B., et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. J. Clin. Invest. 2014, 124:515-527.
31. Camporez J.P., et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 2013, 154:3099-3109.
32. Veniant M.M., et al. Pharmacologic effects of FGF21 are independent of the "browning" of white adipose tissue. Cell Metab. 2015, 21:731-738.
33. Samms R.J., et al. Discrete aspects of FGF21 in vivo pharmacology do not require UCP1. Cell Rep. 2015, 11:991-999.
34. Wu S., et al. Increased expression of fibroblast growth factor 21 (FGF21) during chronic undernutrition causes growth hormone insensitivity in chondrocytes by inducing leptin receptor overlapping transcript (LEPROT) and leptin receptor overlapping transcript-like 1 (LEPROTL1) expression. J. Biol. Chem. 2013, 288:27375-27383.
35. Wei W., et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3143-3148.
36. Owen B.M., et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat. Med. 2013, 19:1153-1156.
37. Sarruf D.A., et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 2010, 59:1817-1824.
38. Bookout A.L., et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat. Med. 2013, 19:1147-1152.
39. Liang Q., et al. FGF21 maintains glucose homeostasis by mediating the crosstalk between liver and brain during prolonged fasting. Diabetes 2014, 63:4064-4075.
40. Douris N., et al. Central fibroblast growth factor 21 browns white fat via sympathetic action in male mice. Endocrinology 2015, 156:2470-2481.
41. Coskun T., et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
42. Hsuchou H., et al. The fasting polypeptide FGF21 can enter brain from blood. Peptides 2007, 28:2382-2386.
43. Micanovic R., et al. Different roles of N- and C- termini in the functional activity of FGF21. J. Cell. Physiol. 2009, 219:227-234.
44. Wu X., et al. C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors. J. Biol. Chem. 2008, 283:33304-33309.
45. Camacho R.C., et al. Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice. Eur. J. Pharmacol. 2013, 715:41-45.
46. Veniant M.M., et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 2012, 153:4192-4203.
47. Huang J., et al. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J. Pharmacol. Exp. Ther. 2013, 346:270-280.
48. Hecht R., et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS ONE 2012, 7:e49345.
49. Smith R., et al. FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/beta-Klotho bispecific protein. PLoS ONE 2013, 8:e61432.
50. Xu J., et al. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation. Bioconjug. Chem. 2013, 24:915-925.
51. Weng Y., et al. Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice. PLoS ONE 2015, 10:e0119104.
52. Mu J., et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 2012, 61:505-512.
53. Huang Z., et al. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS ONE 2011, 6:e20669.
54. Adams A.C., Kharitonenkov A. FGF21, The center of a transcriptional nexus in metabolic regulation. Curr. Diabetes Rev. 2012, 8:285-293.
55. Berglund E.D., et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009, 150:4084-4093.
56. Fisher F.M., et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010, 59:2781-2789.
57. Diaz-Delfin J., et al. TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 2012, 153:4238-4245.
58. Gallego-Escuredo J.M., et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int. J. Obes. 2015, 39:121-129.
59. Hale C., et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 2012, 153:69-80.
60. Gaich G., et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013, 18:333-340.
61. Dong J.Q., et al. Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. Br. J. Clin. Pharmacol. 2015, Published online July 29, 2015. 10.1111/bcp.12676.
62. Hager T., et al. Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities. Anal. Chem. 2013, 85:2731-2738.
63. Galman C., et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 2008, 8:169-174.
64. Badman M.K., et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007, 5:426-437.
65. Inagaki T., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5:415-425.
66. Dushay J., et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139:456-463.
67. Lundasen T., et al. PPARalpha is a key regulator of hepatic FGF21. Biochem. Biophys. Res. Commun. 2007, 360:437-440.
68. Dutchak P.A., et al. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567.
69. Chartoumpekis D.V., et al. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol. Med. 2011, 17:736-740.
70. Kliewer S.A., Mangelsdorf D.J. Fibroblast growth factor 21, from pharmacology to physiology. Am. J. Clin. Nutr. 2010, 91:254S-257S.
71. Markan K.R., et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 2014, 63:4057-4063.
72. Kharitonenkov A., Adams A.C. Inventing new medicines: the FGF21 story. Mol. Metab. 2014, 3:221-229.
73. Suh J.M., et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 2014, 513:436-439.
74. Arafat A.M., et al. Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?. Diabetologia 2013, 56:588-597.
75. Nonogaki K., et al. Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice. BioMed. Res. Int. 2014, 2014:751930.
76. Habegger K.M., et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 2013, 62:1453-1463.
77. Wente W., et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006, 55:2470-2478.
78. So W.Y., et al. Loss of fibroblast growth factor 21 action induces insulin resistance, pancreatic islet hyperplasia and dysfunction in mice. Cell Death Dis. 2015, 6:e1707.
79. Chen W., et al. Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J. Biol. Chem. 2011, 286:34559-34566.
80. Lundberg J., et al. Influence of growth hormone on circulating fibroblast growth factor 21 levels in humans. J. Int. Med. 2013, 274:227-232.
81. Inagaki T., et al. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 2008, 8:77-83.
82. Tomlinson E., et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002, 143:1741-1747.
83. Yang C., et al. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS ONE 2012, 7:e33870.
84. Lundasen T., et al. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J. Int. Med. 2006, 260:530-536.
85. Fu L., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004, 145:2594-2603.
86. Nicholes K., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 2002, 160:2295-2307.
87. Luo Y., et al. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. J. Biol. Chem. 2010, 285:30069-30078.
88. Zhou M., et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res. 2014, 74:3306-3316.
89. Moyers J.S., et al. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J. Cell. Physiol. 2007, 210:1-6.
90. Adams A.C., et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS ONE 2013, 8:e65763.
91. Muller T.D., et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci 2012, 18:383-393.
92. Omar B.A., et al. Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. Diabetes 2014, 63:101-110.
93. Clemmensen C., et al. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 2014, 63:1422-1427.
94. Angelin B., et al. Circulating fibroblast growth factors as metabolic regulators: a critical appraisal. Cell Metab. 2012, 16:693-705.
95. Gimeno R.E., Moller D.E. FGF21-based pharmacotherapy: potential utility for metabolic disorders. Trends Endocrinol. Metab. 2014, 25:303-311.
96. Kharitonenkov A., et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE 2013, 8:e58575.
97. Zhang Y., et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife 2012, 1:e00065.
98. Xu J., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
99. Wynn A., Wynn M. The effects of food shortage on human reproduction. Nutr. Health 1993, 9:43-52.
100. Smith S.M., et al. Fifty years of human space travel: implications for bone and calcium research. Annu. Rev. Nutr. 2014, 34:377-400.